Last reviewed · How we verify
Grafalon
Grafalon is a Small molecule drug developed by St. Anna Kinderkrebsforschung. It is currently FDA-approved. Also known as: Anti-human T-lymphocyte immunoglobulin.
Grafalon is a medication used to treat various conditions, including Renal Transplantation, Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, Acute Myeloid Leukemia (AML), and Myelodysplastic Syndromes (MDS). It is administered as an anti-lymphocyte globulin, typically given at doses of 0.5 mg/kg/day, 1 mg/kg/day, or 2 mg/kg/day for 5 consecutive days.
At a glance
| Generic name | Grafalon |
|---|---|
| Also known as | Anti-human T-lymphocyte immunoglobulin |
| Sponsor | St. Anna Kinderkrebsforschung |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (PHASE2)
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (PHASE3)
- Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (PHASE1, PHASE2)
- Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults (PHASE2)
- GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (PHASE3)
- Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk (PHASE1)
- Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer (PHASE1)
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Grafalon CI brief — competitive landscape report
- Grafalon updates RSS · CI watch RSS
- St. Anna Kinderkrebsforschung portfolio CI
Frequently asked questions about Grafalon
What is Grafalon?
Who makes Grafalon?
Is Grafalon also known as anything else?
What development phase is Grafalon in?
Related
- Manufacturer: St. Anna Kinderkrebsforschung — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Anti-human T-lymphocyte immunoglobulin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing